AtriCure, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K to be signed on our behalf by the undersigned, thereunto duly authorized.
| AtriCure, Inc. | |
| (REGISTRANT) | |
| Date: February 19, 2026 | /s/ Michael H. Carrel |
|---|---|
| Michael H. Carrel | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| Date: February 19, 2026 | /s/ Angela L. Wirick |
| Angela L. Wirick | |
| Chief Financial Officer | |
| (Principal Accounting and Financial Officer) |
KNOW ALL WOMEN AND MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael H. Carrel and Angela L. Wirick, her or his attorney-in-fact, with the power of substitution, for her or him in any and all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and any of them or her or his substitute or substitutes, may do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 19, 2026.
| Signature | Title(s) |
|---|---|
| /s/ Robert S. White | Robert S. White |
| Robert S. White | Chair of the Board |
| /s/ Michael H. Carrel | Michael H. Carrel |
| Michael H. Carrel | Director, President and Chief Executive Officer |
| (Principal Executive Officer) | |
| /s/ Regina E. Groves | Regina E. Groves |
| Regina E. Groves | Director |
| /s/ B. Kristine Johnson | B. Kristine Johnson |
| B. Kristine Johnson | Director |
| /s/ Shlomo Nachman | Shlomo Nachman |
| Shlomo Nachman | Director |
| /s/ Karen N. Prange | Karen N. Prange |
| Karen N. Prange | Director |
| /s/ Deborah H. Telman | Deborah H. Telman |
| Deborah H. Telman | Director |
| /s/ Sven A. Wehrwein | Sven A. Wehrwein |
| Sven A. Wehrwein | Director |
| /s/ Maggie Yuen | Maggie Yuen |
| Maggie Yuen | Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.